FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)

Helliwell, P, Van den Bosch, F, Coates, LC et al. (9 more authors) (2020) FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). In: EULAR 2020, 03-06 Jun 2020, Online.

Metadata

Authors/Creators:
  • Helliwell, P
  • Van den Bosch, F
  • Coates, LC
  • Gladman, DD
  • Tasset, C
  • Meuleners, L
  • Gilles, L
  • Gheyle, L
  • Trivedi, M
  • Alani, M
  • Besuyen, R
  • Mease, PJ
Dates:
  • Published: June 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 29 Sep 2020 15:18
Last Modified: 29 Sep 2020 15:18
Status: Published
Identification Number: https://doi.org/10.1136/annrheumdis-2020-eular.2495
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics